{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-000830","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.651332+00:00","generated_at":"2026-06-07T02:59:08.299590+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AngioDynamics Q2 Revenue $79.1M, Per-Share Loss $0.72; Restructuring Manufacturing; SVP Resigns","bullets":["Net sales $79.1M (up 2.7% pro-forma); GAAP net loss $29.0M or $0.72 per share; adjusted loss $0.05 per share","Initiated restructuring to fully outsource manufacturing; expects $15M annualized cost savings by FY27","David D. Helsel, SVP of Global Operations and R&D, resigns effective Jan 12, 2024 (no disagreement)","Completed enrollment in APEX-AV trial for acute intermediate-risk pulmonary embolism using AlphaVac F18","Revised FY2024 guidance: net sales $320-$325M, gross margin 49-51%, adjusted loss per share $0.35-$0.42"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-000830","json":"https://secwatch.observer/filing/0001140361-24-000830.json","markdown":"https://secwatch.observer/filing/0001140361-24-000830.md","text":"https://secwatch.observer/filing/0001140361-24-000830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124000830/0001140361-24-000830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124000830/ef20017917_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:59:08.299590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6a3ff80df70ff1d2ad797a97823e0380043b039f","claim":"ANGIODYNAMICS INC reported second quarter of fiscal year 2024 ended November 30, 2023 results: revenue $ 79.1 million, net income net loss of $ 29.0 million, EPS loss per share of $0.72.","evidence_excerpt":"Net sales for the second quarter of fiscal year 2024 were $ 79.1 million, an increase of 2.7% compared to the prior-year quarter. Foreign currency translation did not have a significant impact on the Company ' s net sales in the quarter. Med Tech net sales were $ 25.4 million, a 3.5 % increase from $24.5 million in the prior- year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platform. Year-over-year growth was driven by Auryon sales during the quarter of $11.4 million, which increased 12.9%, and AlphaVac sales of $1.9 million, which grew 17.9%. AngioVac sales were $5.4 million in the quarter, a decline of 10.8% from the second quarter of fiscal 2023. The Company completed enrollment of its APEX-AV trial subsequent to quarter end. Med Device net sales were $ 53.7 million, a 2.3% increase from sales of $52.5 in the prior-year period. U.S. net sales in the second quarter of fiscal 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124000830/0001140361-24-000830-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of fiscal year 2024 ended November 30, 2023"},{"label":"Revenue","value":"$ 79.1 million"},{"label":"Net income","value":"net loss of $ 29.0 million"},{"label":"EPS","value":"loss per share of $0.72"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"33dc998c18","claim":"David D. Helsel resigned as Senior Vice President of Global Operations and R&D at ANGIODYNAMICS INC.","evidence_excerpt":"On December 29, 2023, David D. Helsel, Senior Vice President of Global Operations and R&D, notified the Company of his intention to leave the Company, effective January 12, 2024, in order to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124000830/0001140361-24-000830-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Vice President of Global Operations and R&D"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}